Reviews Metastron


No reviews yet.

Metastron Drug Description
METASTRON™
(strontium-89 chloride) Injection
DRUG DESCRIPTION
Metastron is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride
for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity
is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution
is 4 - 7.5.
Physical Characteristics
Strontium-89 decays by beta emission with a physical half-life of 50.5 days.
The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from
Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive
concentration at calibration, when calculating injection volumes at the time
of administration, are given in Table 1.
Table 1: Decay of Strontium-89



Day*
Factor
Day*
Factor


-24
1.39
+6
0.92


-22
1.35
+8
0.90


-20
1.32
+10
0.87


-18
1.28
+12
0.85


-16
1.25
+14
0.83


-14
1.21
+16
0.80


-12
1.18
+18
0.78


-10
1.15
+20
0.76


-8
1.12
+22
0.74


-6
1.09
+24
0.72


-4
1.06
+26
0.70


-2
1.03
+28
0.68


0=calibration
1.00
 
 


* Days before (-) or after (+) the calibration
date stated on the vial.


Last reviewed on RxList: 1/29/2009




Metastron Drug Description
METASTRON™
(strontium-89 chloride) Injection
DRUG DESCRIPTION
Metastron is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride
for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity
is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution
is 4 - 7.5.
Physical Characteristics
Strontium-89 decays by beta emission with a physical half-life of 50.5 days.
The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from
Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive
concentration at calibration, when calculating injection volumes at the time
of administration, are given in Table 1.
Table 1: Decay of Strontium-89



Day*
Factor
Day*
Factor


-24
1.39
+6
0.92


-22
1.35
+8
0.90


-20
1.32
+10
0.87


-18
1.28
+12
0.85


-16
1.25
+14
0.83


-14
1.21
+16
0.80


-12
1.18
+18
0.78


-10
1.15
+20
0.76


-8
1.12
+22
0.74


-6
1.09
+24
0.72


-4
1.06
+26
0.70


-2
1.03
+28
0.68


0=calibration
1.00
 
 


* Days before (-) or after (+) the calibration
date stated on the vial.


Last reviewed on RxList: 1/29/2009




Metastron Drug Description
METASTRON™
(strontium-89 chloride) Injection
DRUG DESCRIPTION
Metastron is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride
for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity
is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution
is 4 - 7.5.
Physical Characteristics
Strontium-89 decays by beta emission with a physical half-life of 50.5 days.
The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from
Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive
concentration at calibration, when calculating injection volumes at the time
of administration, are given in Table 1.
Table 1: Decay of Strontium-89



Day*
Factor
Day*
Factor


-24
1.39
+6
0.92


-22
1.35
+8
0.90


-20
1.32
+10
0.87


-18
1.28
+12
0.85


-16
1.25
+14
0.83


-14
1.21
+16
0.80


-12
1.18
+18
0.78


-10
1.15
+20
0.76


-8
1.12
+22
0.74


-6
1.09
+24
0.72


-4
1.06
+26
0.70


-2
1.03
+28
0.68


0=calibration
1.00
 
 


* Days before (-) or after (+) the calibration
date stated on the vial.


Last reviewed on RxList: 1/29/2009




Metastron Drug Description
METASTRON™
(strontium-89 chloride) Injection
DRUG DESCRIPTION
Metastron is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride
for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity
is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution
is 4 - 7.5.
Physical Characteristics
Strontium-89 decays by beta emission with a physical half-life of 50.5 days.
The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from
Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive
concentration at calibration, when calculating injection volumes at the time
of administration, are given in Table 1.
Table 1: Decay of Strontium-89



Day*
Factor
Day*
Factor


-24
1.39
+6
0.92


-22
1.35
+8
0.90


-20
1.32
+10
0.87


-18
1.28
+12
0.85


-16
1.25
+14
0.83


-14
1.21
+16
0.80


-12
1.18
+18
0.78


-10
1.15
+20
0.76


-8
1.12
+22
0.74


-6
1.09
+24
0.72


-4
1.06
+26
0.70


-2
1.03
+28
0.68


0=calibration
1.00
 
 


* Days before (-) or after (+) the calibration
date stated on the vial.


Last reviewed on RxList: 1/29/2009




Metastron Drug Description
METASTRON™
(strontium-89 chloride) Injection
DRUG DESCRIPTION
Metastron is a sterile, non-pyrogenic, aqueus solution of St rontium-89 Chloride
for intravenous administration. The solution contains no preservative.
Each milliliter contains:
Strontium< Chloride 10.9 - 22.6 mg
Water for Injection q.s. to 1 mL
The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity
is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution
is 4 - 7.5.
Physical Characteristics
Strontium-89 decays by beta emission with a physical half-life of 50.5 days.
The maximum beta energy is 1.463 MeV (100%). The maximum range of β- from
Strontium-89 in tissue is approximately 8 mm.
Radioactive decay factors to be applied to the stated value for radioactive
concentration at calibration, when calculating injection volumes at the time
of administration, are given in Table 1.
Table 1: Decay of Strontium-89



Day*
Factor
Day*
Factor


-24
1.39
+6
0.92


-22
1.35
+8
0.90


-20
1.32
+10
0.87


-18
1.28
+12
0.85


-16
1.25
+14
0.83


-14
1.21
+16
0.80


-12
1.18
+18
0.78


-10
1.15
+20
0.76


-8
1.12
+22
0.74


-6
1.09
+24
0.72


-4
1.06
+26
0.70


-2
1.03
+28
0.68


0=calibration
1.00
 
 


* Days before (-) or after (+) the calibration
date stated on the vial.


Last reviewed on RxList: 1/29/2009





Other reviews about Metastron on wordpress

The news report: Wednesday, April 22
  by Sitemaster
Today's news reports deal with: A gene modification that may identify risk for prostate cancer Dietary intervention and prostate cancer management "Elastography" as a possible means to assess risk for prostate […]


Bayer’s Bold New Bet Fails to Rain on Spectrum Pharmaceuticals
  by Michael Becker
By Michael D. Becker Despite recent progress and the availability of novel therapies, radiation is still an effective tool in the war against cancer – as it has been […]


I've seen a few articles about the effect of strontium supplements on osteoporosis. What do you think?
  by sherribetz
Response from Gayle Nicholas Scott, PharmD, BCPS, ELS Assistant Professor, Eastern Virginia Medical School, Norfolk, Virginia; Clinical Pharmacist, Chesapeake Regional Medical Center, Chesapeake, Virginia Strontium is located on the periodic […]


MEASURED REACTOR EMISSIONS
  by nuclearhistory
The Myth of Zero Emission Nuclear Power Plants. In the course of normal, routine, daily operation, nuclear power plants emit radioactive substances, in the form of fine aerosols, into […]


Radiation Hormesis
  by nuclearhistory
Marshall Brucer (1913-1994) was the author of "A Chronology of Nuclear Medicine", Heritage Publications Inc, St Louis, ISBN 0-9625674-0-x, 1990,. Brucer was one of the most honoured post […]



Other reviews about Metastron on web:

Learn about the prescription medication Metastron (Strontium-89), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Metastron (Strontium-89) Drug Information: Uses, Side Effects ...


Accurate, FDA approved Metastron information for healthcare professionals and patients - brought to you by Drugs.com. Metastron Official FDA information, side effects and uses.


Metastron patient information. Detailed drug information for the consumer, includes dosage, Metastron side effects and more. Metastron consumer information from Drugs.com


Find patient medical information for Metastron IV on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Metastron IV : Uses, Side Effects, Interactions, Pictures ...


An intravenously administered radioisotope that provides pain relief for patients suffering from bone pain due to metastatic prostate cancer. The active agent, strontium-89, is a ... GE Healthcare-Product Specifications-Metastron


Consumer information about the medication STRONTIUM-89 CHLORIDE - INTRAVENOUS (Metastron), includes side effects, drug interactions, recommended dosages, and storage information. STRONTIUM-89 CHLORIDE - INTRAVENOUS (Metastron) side effects ...


What class of treatment is Metastron (Strontium 89 Chloride)? Category: Radiologic Agents / Radiopharmaceuticals / Therapeutic Radiopharmaceuticals Metastron - Drugs & Treatments - Revolution Health


1 What is Metastron? Metastron is an injection developed to relieve the pain in your bones caused by your illness. In the body, Metastron acts like calcium, clearing rapidly from the ... What is Metastron?


Metastron Information, Learn About Metastron, Metastron Forums, How to Take Metastron, Metastron Side Effects, Metastron Interactions, Discussion Threads, Medication Warnings ... Metastron - The People's Medicine Community


About Your Treatment. Your doctor has ordered the drug strontium-89 chloride to help treat your illness. The drug is given by injection into a vein or a catheter that has been placed ... Metastron - Kosmix : Reference, Videos, Images, News, Shopping and ...





Featured Reviews

Reviews Isoniazid

Nydrazid Drug Description DRUG DESCRIPTION WARNING: Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported and may occur or may develop even after many months of treatment. The risk of developing...
Read More  |  Review This
Reviews Imipenem and Cilastatin

Primaxin IM Drug Description PRIMAXIN® I.M. (imipenem and cilastatin) for Injectable Suspension To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN I.M.† and other antibacterial...
Read More  |  Review This
Reviews Albumin-bound Paclitaxel

Abraxane Drug Description ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles) for Injectable Suspension (albumin-bound) WARNING ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles...
Read More  |  Review This
Reviews Dyazide

Dyazide Drug Description Dyazide (hydrochlorothiazide/triamterene) Capsules DRUG DESCRIPTION What are the possible side effects of hydrochlorothiazide and triamterene (Dyazide, Maxzide, Maxzide-25)? Get emergency medical help...
Read More  |  Review This
Reviews Extina

Extina Drug Description Extina® (ketoconazole foam, 2%) For topical use only DRUG DESCRIPTION What are the possible side effects of ketoconazole topical (Extina, Kuric, Nizoral A-D, Nizoral Topical, Xolegel)? Get emergency...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....